Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER

Heart Failure

Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial

Eur J Heart Fail

Lassen MCH, Ostrominski JW, Inzucchi SE, Claggett BL, Kulac I, Jhund P, de Boer RA, Hernandez AF, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Desai AS, Petersson M, Langkilde AM, Docherty KF, McMurray JJV, Solomon SD, Vaduganathan M

doi: 10.1002/ejhf.3269

Heart Failure

Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HF

Eur J Heart Fail

Wang X, Vardeny O, Claggett B, Vaduganathan M, Hegde SM, Skali H, Pabon MA, Foà A, Chatur S, Kosztin A, O'Meara E, Rouleau J, Redfield M, Lam CSP, Zile M, Packer M, Shah AM, Cikes M, Gori M, Merkely B, Pfeffer MA, McMurray JJV, Solomon SD

doi: 10.1002/ejhf.3535

Heart Failure

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial

Eur J Heart Fail

Tromp J, Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Brueckmann M, Blatchford JP, Steubl D, Voors AA

doi: 10.1002/ejhf.3218

Heart Failure

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries - A Global Congestive Heart Failure (G-CHF) study

Eur J Heart Fail

Leong DP, Joseph PG, Dokainish H, Störk S, McMurray JVV, Mielniczuk LM, Sharma SK, Orlandini A, Karaye KM, Bayes-Genis A, McCready T, Grinvalds A, Balasubramanian K, Branch KR, Kragholm K, Yusuf S, on behalf of the G‐CHF Investigators

doi: 10.1002/ejhf.3550

Heart Failure

Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry

Eur J Heart Fail

Cao TH, Tay WT, Jones DJL, Cleland JGF, Tromp J, Emmens JE, Teng TK, Chandramouli C, Slingsby OC, Anker SD, Dickstein K, Filippatos G, Lang CC, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Anand IS, Lam CSP, Voors AA, Ng LL

doi: 10.1002/ejhf.3378

Heart Failure

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Eur J Heart Fail

Shahim A, Linde C, Savarese G, Dahlström U, Lund LH, Hage C

doi: 10.1002/ejhf.3565

Heart Failure

Investigation of left ventricular ejection fraction in a Swiss heart failure population: Insights into mortality and sex differences

ESC Heart Fail

Fuentes Artiles R, Meçani R, Muka T, Hunziker L, Capék L

doi: 10.1002/ehf2.15174

Heart FailureFurther Publications

Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial

JAMA Cardiol

Patel RB, Silvestry FE, Komtebedde J, Solomon SD, Hasenfuß G, Litwin SE, Borlaug BA, Price MJ, Kawash R, Hummel SL, Cutlip DE, Leon MB, van Veldhuisen DJ, Rieth AJ, McKenzie S, Bugger H, Mazurek JA, Kapadia SR, Vanderheyden M, Ky B, Shah SJ

doi: 10.1001/jamacardio.2024.0520

Heart Failure

Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

JAMA Cardiol

Chimura M, Wang X, Jhund PS, Henderson AD, Claggett BL, Desai AS, Fonseca C, Goncalvesova E, Katova T, Mueller K, Glasauer A, Rohwedder K, Viswanathan P, Nodari S, Lam CSP, Saldarriaga CI, Senni M, Sharma K, Voors AA, Zannad F, Pitt B, Vardeny O, Vaduganathan M, Solomon SD, McMurray JJV

doi: 10.1001/jamacardio.2024.4613

Related content

Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial

Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON-HF

Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial

The risk of death according to left ventricular ejection fraction and right ventricular dilatation in 17 321 adults with heart failure from 40 high-, middle- and low-income countries - A Global Congestive Heart Failure (G-CHF) study

Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT-CHF (European) study with the ASIAN-HF registry

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Investigation of left ventricular ejection fraction in a Swiss heart failure population: Insights into mortality and sex differences

Atrial Shunt Device Effects on Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: The REDUCE LAP-HF II Randomized Clinical Trial

Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial